For example, dabrafenib in combination with trametinib is used for the treatment of patients with BRAF-mutation-positive metastatic NSCLC22; dabrafenib plus trametinib is used for adjuvant treatment after surgery in patients with BRAF-V600-mutation-positive stage III melanoma23; vemurafenib is used for the treatment of patients with BRAF-V600-mutation-positive advanced melanoma,24 and so forth. This evidence concerns the gene BRAF and melanoma.